65 related articles for article (PubMed ID: 38494863)
21. Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and/or CD40.
Wenthe J; Naseri S; Hellström AC; Wiklund HJ; Eriksson E; Loskog A
Cancer Gene Ther; 2020 Dec; 27(12):948-959. PubMed ID: 32355275
[TBL] [Abstract][Full Text] [Related]
22. Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer.
Ma J; Ramachandran M; Jin C; Quijano-Rubio C; Martikainen M; Yu D; Essand M
Cell Death Dis; 2020 Jan; 11(1):48. PubMed ID: 31969562
[TBL] [Abstract][Full Text] [Related]
23. The Oncolytic Virus
Di Somma S; Iannuzzi CA; Passaro C; Forte IM; Iannone R; Gigantino V; Indovina P; Botti G; Giordano A; Formisano P; Portella G; Malfitano AM; Pentimalli F
Front Oncol; 2019; 9():564. PubMed ID: 31355131
[No Abstract] [Full Text] [Related]
24. Enhanced antitumor efficacy of an oncolytic adenovirus armed with an EGFR-targeted BiTE using menstrual blood-derived mesenchymal stem cells as carriers.
Barlabé P; Sostoa J; Fajardo CA; Alemany R; Moreno R
Cancer Gene Ther; 2020 May; 27(5):383-388. PubMed ID: 31204390
[TBL] [Abstract][Full Text] [Related]
25. IL-6 Signaling Blockade during CD40-Mediated Immune Activation Favors Antitumor Factors by Reducing TGF-β, Collagen Type I, and PD-L1/PD-1.
Eriksson E; Milenova I; Wenthe J; Moreno R; Alemany R; Loskog A
J Immunol; 2019 Feb; 202(3):787-798. PubMed ID: 30617223
[TBL] [Abstract][Full Text] [Related]
26. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
[TBL] [Abstract][Full Text] [Related]
27. Shaping the Tumor Stroma and Sparking Immune Activation by CD40 and 4-1BB Signaling Induced by an Armed Oncolytic Virus.
Eriksson E; Milenova I; Wenthe J; Ståhle M; Leja-Jarblad J; Ullenhag G; Dimberg A; Moreno R; Alemany R; Loskog A
Clin Cancer Res; 2017 Oct; 23(19):5846-5857. PubMed ID: 28536305
[No Abstract] [Full Text] [Related]
28. Activation of myeloid and endothelial cells by CD40L gene therapy supports T-cell expansion and migration into the tumor microenvironment.
Eriksson E; Moreno R; Milenova I; Liljenfeldt L; Dieterich LC; Christiansson L; Karlsson H; Ullenhag G; Mangsbo SM; Dimberg A; Alemany R; Loskog A
Gene Ther; 2017 Feb; 24(2):92-103. PubMed ID: 27906162
[TBL] [Abstract][Full Text] [Related]
29. A redox state-dictated signalling pathway deciphers the malignant cell specificity of CD40-mediated apoptosis.
Dunnill CJ; Ibraheem K; Mohamed A; Southgate J; Georgopoulos NT
Oncogene; 2017 May; 36(18):2515-2528. PubMed ID: 27869172
[TBL] [Abstract][Full Text] [Related]
30. Expansion of NK cells from PBMCs using immobilized 4-1BBL and interleukin-21.
Li X; He C; Liu C; Ma J; Ma P; Cui H; Tao H; Gao B
Int J Oncol; 2015 Jul; 47(1):335-42. PubMed ID: 25975533
[TBL] [Abstract][Full Text] [Related]
31. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy.
Jiang H; Fueyo J
Oncoimmunology; 2014; 3(7):e947872. PubMed ID: 25954598
[TBL] [Abstract][Full Text] [Related]
32. Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization.
Willoughby JE; Kerr JP; Rogel A; Taraban VY; Buchan SL; Johnson PW; Al-Shamkhani A
J Immunol; 2014 Jul; 193(1):244-51. PubMed ID: 24860188
[TBL] [Abstract][Full Text] [Related]
33. Oncolytic Immunotherapy: Dying the Right Way is a Key to Eliciting Potent Antitumor Immunity.
Guo ZS; Liu Z; Bartlett DL
Front Oncol; 2014; 4():74. PubMed ID: 24782985
[TBL] [Abstract][Full Text] [Related]
34. Immunogenic cell death in cancer therapy.
Kroemer G; Galluzzi L; Kepp O; Zitvogel L
Annu Rev Immunol; 2013; 31():51-72. PubMed ID: 23157435
[TBL] [Abstract][Full Text] [Related]
35. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice.
Michaud M; Martins I; Sukkurwala AQ; Adjemian S; Ma Y; Pellegatti P; Shen S; Kepp O; Scoazec M; Mignot G; Rello-Varona S; Tailler M; Menger L; Vacchelli E; Galluzzi L; Ghiringhelli F; di Virgilio F; Zitvogel L; Kroemer G
Science; 2011 Dec; 334(6062):1573-7. PubMed ID: 22174255
[TBL] [Abstract][Full Text] [Related]
36. CD91-dependent programming of T-helper cell responses following heat shock protein immunization.
Pawaria S; Binder RJ
Nat Commun; 2011 Nov; 2():521. PubMed ID: 22045000
[TBL] [Abstract][Full Text] [Related]
37. Calreticulin exposure on malignant blasts predicts a cellular anticancer immune response in patients with acute myeloid leukemia.
Wemeau M; Kepp O; Tesnière A; Panaretakis T; Flament C; De Botton S; Zitvogel L; Kroemer G; Chaput N
Cell Death Dis; 2010 Dec; 1(12):e104. PubMed ID: 21368877
[TBL] [Abstract][Full Text] [Related]
38. Expression of calreticulin is associated with infiltration of T-cells in stage IIIB colon cancer.
Peng RQ; Chen YB; Ding Y; Zhang R; Zhang X; Yu XJ; Zhou ZW; Zeng YX; Zhang XS
World J Gastroenterol; 2010 May; 16(19):2428-34. PubMed ID: 20480531
[TBL] [Abstract][Full Text] [Related]
39. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance.
Elliott MR; Chekeni FB; Trampont PC; Lazarowski ER; Kadl A; Walk SF; Park D; Woodson RI; Ostankovich M; Sharma P; Lysiak JJ; Harden TK; Leitinger N; Ravichandran KS
Nature; 2009 Sep; 461(7261):282-6. PubMed ID: 19741708
[TBL] [Abstract][Full Text] [Related]
40. Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region.
Danielsson A; Dzojic H; Nilsson B; Essand M
Cancer Gene Ther; 2008 Apr; 15(4):203-13. PubMed ID: 18188185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
